Compare ACM Research Inc (ACMR) vs Tilray Brands Inc (TLRY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACM Research Inc vs Tilray Brands Inc — how do they compare? ACM Research Inc trades at $96.54 (market cap $6.54B), while Tilray Brands Inc trades at $4.33 (market cap $532.10M). The key difference: ACM Research Inc is far larger — about 12.3× Tilray Brands Inc's market cap, and ACM Research Inc is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals.
| ACMR | TLRY | |
|---|---|---|
Market Cap | $6.54B | $532.10M |
Sector | Technology | Health |
52-Week High | $126.89 | $21.00 |
52-Week Low | $23.92 | $4.31 |
Enterprise Value | $5.61B | $629.24M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACMR trades at $98.52, up 0.77% today, with a bullish technical signal from moving averages and a consensus analyst price target of $110. Recent earnings showed a Q1 2026 beat but misses in prior quarters. Revenue grew to $901 million in 2025, though net income margins are under pressure. The stock has experienced volatility, with news highlighting semiconductor sector catalysts and a GF Score of 82 (GuruFocus, June 25, 2026).
Outlook is positive with 80% analyst buy ratings and semiconductor demand tailwinds, but risks include earnings inconsistency, high valuation multiples, and negative operating cash flow. Investors should weigh growth potential against execution risks in a competitive market.
TLRY trades at $4.38, down 5.19% today, reflecting ongoing investor concerns about profitability despite revenue growth to $821 million in 2025. The stock shows bearish technical signals with key support at $4 and resistance at $5. Recent acquisitions and medical cannabis expansion provide growth avenues, but negative net income margins and cash flow challenges persist. Analyst consensus remains cautious with 65% hold ratings.
TLRY presents a high-risk opportunity with potential upside from strategic acquisitions and market expansion, but significant challenges include persistent losses, negative cash flow, and regulatory uncertainties. The stock's low P/S (0.54) and P/B (0.35) ratios suggest undervaluation, but profitability remains the critical hurdle for sustainable growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACM Research Inc
ACM Research develops and manufactures semiconductor process equipment, specializing in wafer cleaning and electroplating solutions. Its tools are used by global chipmakers to improve productivity and yield for logic and memory chips.
Read more on ACMR →About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →
